분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2018-04-17 11:48:14 , Hit : 235
 CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides

https://www.genengnews.com/gen-news-highlights/crispr-cas9-improved-10-000-fold-by-synthetic-nucleotides/81255705/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20180416&ajs_trait_oebid=9675b9130356b7s

GEN News Highlights

April 16, 2018

Scientists at the University of Alberta in Canada have developed a technology that can dramatically improve the specificity of CRISPR-Cas9 gene editing. The approach uses synthetic guide molecules known as bridged nucleic acids (BNAs) in place of the system’s native guide RNAs (gRNAs) to direct the Cas9 enzyme to its target DNA sequence, and so reduce off-target DNA cleavage.

“We've discovered a way to greatly improve the accuracy of gene-editing technology by replacing the natural guide molecule it uses with a synthetic one called a bridged nucleic acid, or BNA,” claims lead researcher Basil Hubbard, Ph.D., Canada Research Chair in Molecular Therapeutics and assistant professor at the University of Alberta’s Department of Pharmacology. “Our research shows that the use of bridged nucleic acids to guide Cas9 can improve its specificity by over 10,000 times in certain instances—a dramatic improvement.”

The University of Alberta team and colleagues at Seoul National University in Korea, report on the new technology in Nature Communications, in a paper entitled “Incorporation of Bridged Nucleic Acids into CRISPR RNAs Improves Cas9 Endonuclease Specificity.”

The CRISPR-Cas9 system has become a key genome-editing tool that has widespread applications in fields spanning model organisms, functional genomics, and epigenetic screens, and potentially human therapeutics. However, the University of Alberta team points out, the system isn’t foolproof, and while 99% of the time the Cas9 enzyme cuts DNA at precisely the right sequence, about 1% of the time it will cut the DNA at the wrong site. “…the system is not perfectly specific,” Dr. Hubbard comments. “…sometimes it cuts a similar but incorrect gene. However, given that there are trillions of cells in the human body, even one percentage off is quite significant, especially because gene editing is permanent. One wrong cut and a patient could end up with a serious condition like cancer."

Two noncoding RNA elements are involved in directing the Cas9 enzyme to cleave at its target sequence, the University of Alberta team continues. “The CRISPR-RNA (crRNA) contains a 20-nucleotide (nt) RNA sequence complementary to the target DNA sequence, while the transactivating crRNA (tracrRNA) acts as a bridge between the crRNA and Cas9 enzyme.” Hybridization of these two elements constitutes the gRNA.

The specificity of Cas9 DNA cleavage is highly dependent on the crRNA sequence and target-crRNA folding stability, and mutations within the target sequence can result in cleavage at off-target DNA sequences. However, while various approaches have been used to improve Cas9 specificity, “off-target cutting and generation of accessory mutations remains a significant barrier for Cas9-based gene editing.”

Most of the approaches to improving specificity have involved modifying the Cas9 enzyme itself, but the University of Alberta researchers have instead focused on incorporating synthetic nucleotides—BNAs—at specific locations in crRNAs. “Interestingly, bridged nucleic acids (BNAs) have previously been shown to improve mismatch discrimination in nucleic acid duplexes,” they point out. “We hypothesized that incorporation of these synthetic nucleotides into crRNAs could improve Cas9 DNA cleavage specificity.”

Initial in vitro tests showed that incorporating BNA-modified nucleotides into crRNAs broadly improved Cas9 specificity and reduced off-target cleavage. Encouragingly, the BNA-substituted crRNAs were also compatible with Cas9 variants that scientists have generated independently to try and reduce off-target Cas9 activity. “Strikingly, we found that the combination was additive, resulting in elimination of nearly all off-target activity,” say the researchers commenting on the results from testing one combination of modified crRNA and engineered Cas9 and stating that the BNA-modified crRNAs “can complement the specificity enhancements of next-generation Cas9 variants.” Subsequent tests confirmed that the BNA-modified crRNAs induced lower cleavage rates at off-targets sites in cultured cells, as well as in vitro.

Analyses designed to identify the mechanisms at work indicated that the BNA-substituted crRNAs enhance specificity both by slowing Cas9 kinetics and by impairing formation on off-target sites, of the stable “zipped” conformation that is prerequisite for DNA cleavage. Interestingly, using locked nucleic acids (LNAs) substitutions in the crRNAs instead of BNAs also increased Cas9 specificity, but to a lesser extent than the BNA-substituted crRNAs.

“Overall, these findings unveil a strategy for improving the specificity of the CRISPR-Cas9 system and illustrate the application of recently developed synthetic nucleic acid technologies to solving problems in enzyme specificity,” the researchers conclude. “We anticipate that these findings will directly contribute to the ongoing goal of improving the specificity and safety of genome-editing agents for a wide variety of experimental and clinical applications.…In addition to describing a robust technique for improving the precision of CRISPR/Cas9-based gene editing, this study illuminates an application of synthetic nucleic acids.”







1238   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 154
1237   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 143
1236   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 144
1235   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 223
  CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 235
1233   Nature Methods retracts CRISPR study  이성욱 2018/04/10 443
1232   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 270
1231   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 280
1230   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 466
1229   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 366
1228   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 454
1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 447
1226   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 414
1225   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 361
1224   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 363
1223   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 338
1222   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 368
1221   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 341
1220   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 245
1219   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 330

[1] 2 [3][4][5][6][7][8][9][10]..[63] [다음 10개]
 

Copyright 1999-2018 Zeroboard / skin by ROBIN